A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma. We’re keeping the same guidelines used for last ...

Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its pipeline of obesity therapies. The Waltham, Massachusetts-headquartered ...

State Street SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) have delivered strong returns of 40.80% and 33.95% respectively over the trailing year, but their equal-weight versus market ...

A major biotech company is leaving the Bay Area. Pfizer is abandoning its research site at 181 Oyster Point Blvd. in South San Francisco. The biotech company will move out of the building by the end ...

This year’s crop of biotechnology IPOs features an unusual star in an industry better known for targeting severe diseases: Veradermics, whose shares have rocketed on the potential of its hair-loss ...

– Today, Alloy has over 200 partners with over 100 licensed therapeutic programs, including 22 in clinical development – Powered by AI integrated with real-world data and wet lab execution, Alloy ...

(KRON) — One of the world’s largest biotech companies is closing its only office in the Bay Area. Pfizer is shutting down its office space in South San Francisco this month, the company said in a ...

While the company — focused on treating a rare lung disease — has other drugs in the pipeline, the question remains whether Gossamer has the money and manpower to continue with the costly trials. The ...

April 13 (Reuters) - Alamar Biosciences and Kailera Therapeutics kicked off roadshows for their U.S. initial public offerings on Monday, aiming for billion-dollar-plus valuations ‌as biotech companies ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Bell Linn: Welcome to Tech News Briefing. It's Friday, April 10th. I'm Bell Linn ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Boston biotech co-founded by ...